Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cambridge Neuroscience

Executive Summary

Former Warner-Lambert exec Elkan Gamzu, PhD, named to new position of VP-development of the CNS drug R&D firm, effective Oct. 1. Gamzu led the Tacrine (THA) clinical trials while at W-L, where he was VP-drug development for Parke-Davis. Gamzu will continue to handle the Tacrine development. He has agreed to stay on as a consultant until the NDA filing for the Alzheimer's drug. Fred Hershenson, PhD, succeeds Gamzu at Parke-Davis. He has been with Warner-Lambert seven years, most recently as senior director in charge of CNS chemistry.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS016240

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel